Akebia Deferred Long Term Liab vs Net Working Capital Analysis
AKBA Stock | USD 2.06 0.01 0.49% |
Akebia Ther financial indicator trend analysis is way more than just evaluating Akebia Ther prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Akebia Ther is a good investment. Please check the relationship between Akebia Ther Deferred Long Term Liab and its Net Working Capital accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akebia Ther. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. For information on how to trade Akebia Stock refer to our How to Trade Akebia Stock guide.
Deferred Long Term Liab vs Net Working Capital
Deferred Long Term Liab vs Net Working Capital Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Akebia Ther Deferred Long Term Liab account and Net Working Capital. At this time, the significance of the direction appears to have almost no relationship.
The correlation between Akebia Ther's Deferred Long Term Liab and Net Working Capital is 0.19. Overlapping area represents the amount of variation of Deferred Long Term Liab that can explain the historical movement of Net Working Capital in the same time period over historical financial statements of Akebia Ther, assuming nothing else is changed. The correlation between historical values of Akebia Ther's Deferred Long Term Liab and Net Working Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Deferred Long Term Liab of Akebia Ther are associated (or correlated) with its Net Working Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Working Capital has no effect on the direction of Deferred Long Term Liab i.e., Akebia Ther's Deferred Long Term Liab and Net Working Capital go up and down completely randomly.
Correlation Coefficient | 0.19 |
Relationship Direction | Positive |
Relationship Strength | Insignificant |
Deferred Long Term Liab
Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.Net Working Capital
Most indicators from Akebia Ther's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Akebia Ther current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akebia Ther. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. For information on how to trade Akebia Stock refer to our How to Trade Akebia Stock guide.The current year's Enterprise Value is expected to grow to about 394.5 M, whereas Selling General Administrative is forecasted to decline to about 3.1 M.
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 19.9M | 15.7M | 6.0M | 9.4M | Depreciation And Amortization | 38.0M | 35.3M | 37.6M | 39.5M |
Akebia Ther fundamental ratios Correlations
Click cells to compare fundamentals
Akebia Ther Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Akebia Ther fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 771.2M | 644.1M | 525.6M | 351.8M | 241.7M | 411.2M | |
Other Current Liab | 124.1M | 125.3M | 104.2M | 71.0M | 61.2M | 67.9M | |
Total Current Liabilities | 208.1M | 187.1M | 256.5M | 124.8M | 99.9M | 130.9M | |
Total Stockholder Equity | 394.8M | 247.6M | 76.5M | 9.3M | (30.6M) | (29.1M) | |
Net Debt | (39.1M) | (102.4M) | (13.8M) | 9.3M | 61.3M | 64.3M | |
Retained Earnings | (794.1M) | (1.2B) | (1.5B) | (1.6B) | (1.6B) | (1.5B) | |
Accounts Payable | 39.2M | 41.3M | 33.6M | 18.0M | 14.6M | 18.7M | |
Cash | 147.4M | 228.7M | 149.8M | 90.5M | 42.9M | 40.8M | |
Cash And Short Term Investments | 147.7M | 268.7M | 149.8M | 90.5M | 42.9M | 40.8M | |
Net Receivables | 38.9M | 26.9M | 51.6M | 41.1M | 39.3M | 28.3M | |
Common Stock Shares Outstanding | 118.4M | 138.5M | 165.9M | 182.8M | 187.5M | 97.4M | |
Liabilities And Stockholders Equity | 771.2M | 644.1M | 525.6M | 351.8M | 241.7M | 411.2M | |
Other Current Assets | 6.6M | 14.9M | 33.1M | 32.9M | 20.2M | 12.6M | |
Total Liab | 376.4M | 396.5M | 449.1M | 342.5M | 272.3M | 247.7M | |
Total Current Assets | 309.5M | 371.4M | 272.0M | 184.9M | 118.1M | 112.2M | |
Short Long Term Debt Total | 108.3M | 126.3M | 136.0M | 99.8M | 104.2M | 72.1M | |
Property Plant And Equipment Net | 39.4M | 35.5M | 40.6M | 34.4M | 16.0M | 18.1M | |
Non Current Assets Total | 461.7M | 272.7M | 253.5M | 166.9M | 123.6M | 182.0M | |
Non Currrent Assets Other | 76.0M | 38.0M | 49.8M | 5.4M | 12.4M | 20.8M | |
Other Assets | 76.0M | 64.9M | 640.3M | 94.5M | 108.7M | 112.1M | |
Non Current Liabilities Total | 168.3M | 209.4M | 192.6M | 217.7M | 172.4M | 127.4M | |
Other Stockholder Equity | 1.2B | 1.4B | 1.5B | 1.6B | 1.6B | 973.5M | |
Property Plant And Equipment Gross | 10.4M | 35.5M | 48.3M | 43.7M | 16.0M | 16.9M | |
Accumulated Other Comprehensive Income | (261K) | 0.0 | 13K | 6K | 6.9K | 7.2K | |
Short Term Debt | 5.0M | 5.3M | 102.3M | 36.7M | 24.0M | 20.8M | |
Property Plant Equipment | 10.4M | 8.6M | 6.8M | 5.2M | 6.0M | 5.1M | |
Other Liab | 65.0M | 88.4M | 158.9M | 158.2M | 182.0M | 95.8M | |
Net Tangible Assets | 48.5M | 48.4M | (86.7M) | (117.8M) | (106.0M) | (100.7M) | |
Retained Earnings Total Equity | (794.1M) | (1.2B) | (1.5B) | (1.6B) | (1.4B) | (1.3B) | |
Capital Surpluse | 1.2B | 1.4B | 1.5B | 1.6B | 1.8B | 1.0B | |
Inventory | 116.3M | 61.0M | 38.2M | 21.8M | 15.7M | 14.9M | |
Non Current Liabilities Other | 90.9M | 110.6M | 190.8M | 98.5M | 62.9M | 70.3M | |
Intangible Assets | 291.2M | 144.2M | 108.1M | 72.1M | 36.0M | 34.2M | |
Current Deferred Revenue | 39.8M | 15.2M | 20.9M | 3.7M | 22.9M | 29.0M | |
Net Invested Capital | 470.6M | 344.0M | 174.0M | 75.4M | 4.1M | 3.9M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Akebia Ther offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Akebia Ther's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Akebia Ther Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Akebia Ther Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akebia Ther. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. For information on how to trade Akebia Stock refer to our How to Trade Akebia Stock guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akebia Ther. If investors know Akebia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akebia Ther listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.22) | Revenue Per Share 0.834 | Quarterly Revenue Growth (0.11) | Return On Assets (0.09) | Return On Equity (5.53) |
The market value of Akebia Ther is measured differently than its book value, which is the value of Akebia that is recorded on the company's balance sheet. Investors also form their own opinion of Akebia Ther's value that differs from its market value or its book value, called intrinsic value, which is Akebia Ther's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akebia Ther's market value can be influenced by many factors that don't directly affect Akebia Ther's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akebia Ther's value and its price as these two are different measures arrived at by different means. Investors typically determine if Akebia Ther is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akebia Ther's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.